Why Neuren Pharmaceuticals stock is in focus now
Neuren Pharmaceuticals (ASX:NEU) has caught investor attention after reporting half year 2026 results showing higher sales and revenue, a lower net profit figure, and the declaration of a fully franked interim dividend.
Neuren Pharmaceuticals shares trade at A$19.89, with a 90 day share price return of 46.36% and a 30 day share price return of 10.50%. This comes despite a 7 day share price pullback of 11.72%, while the 5 year total shareholder return is about 7x. This indicates notable long term momentum alongside a recent reset in expectations around the latest earnings and dividend news.
Compare Neuren Pharmaceuticals' earnings and dividend update with other companies showing strong momentum and solid fundamentals in our hand picked 12 high quality undervalued stocks.
After a sharp multi month run, a recent pullback and a smaller half year profit, the question now is simple: Does Neuren Pharmaceuticals still offer enough upside potential to justify the risks at today’s price, based on its current valuation?
Price-to-Earnings of 124.5x for Neuren Pharmaceuticals: Is it justified?
On traditional valuation metrics, Neuren Pharmaceuticals looks expensive. The stock trades on a P/E of 124.5x at a last close of A$19.89, while analysts also see upside to a target price of A$25.79 and the SWS DCF model flags a very large gap between price and its estimated cash flow value.
The P/E ratio compares the current share price to earnings per share. For a biopharmaceutical company like Neuren Pharmaceuticals, this often reflects how much future earnings growth and commercial success investors are willing to price in today, given its portfolio of approved and pipeline treatments.
Here, the market is paying a much higher multiple than both the estimated fair P/E of 52.4x and the broader Global Pharmaceuticals industry average of 22.2x. That points to a valuation where expectations for future earnings and revenue growth are already very ambitious, and the fair ratio level of 52.4x shows how far the multiple could move if sentiment and assumptions revert closer to that benchmark.
Explore the SWS fair ratio for Neuren Pharmaceuticals
Result: Price-to-Earnings of 124.5x (OVERVALUED)
However, investors also need to weigh risks, including Neuren Pharmaceuticals’ reliance on A$69.5m of United States revenue and the high P/E multiple if growth expectations soften.
Find out about the key risks to this Neuren Pharmaceuticals narrative.
Another View on Neuren Pharmaceuticals valuation
The SWS DCF model paints a very different picture for Neuren Pharmaceuticals. At A$19.89, the stock is assessed as trading well below an estimated future cash flow value of A$165.49. That suggests the market price could be heavily discounting the company’s long term cash generation. Which lens do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Neuren Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 12 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With such a mixed picture around Neuren Pharmaceuticals, it may be useful to act promptly and consider both the concerns and the potential upside for yourself. To see the full balance of issues investors are flagging, including 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Neuren Pharmaceuticals?
If Neuren Pharmaceuticals has sharpened your focus on valuation, do not stop here. Use the next few minutes to explore additional opportunities for your watchlist.
- Prioritize resilience and reduce unwanted shocks by scanning a 14 resilient stocks with low risk scores that filters for companies with steadier profiles.
- Identify potential value opportunities and compare valuations efficiently using the 12 high quality undervalued stocks tailored to highlight companies with solid fundamentals.
- Explore under followed prospects that may not yet be widely tracked by reviewing the 12 high quality undiscovered gems before they draw broader attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com